Leap Therapeutics (LPTX)
(Delayed Data from NSDQ)
$2.71 USD
-0.06 (-2.17%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $2.72 +0.01 (0.37%) 5:48 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Leap Therapeutics, Inc. [LPTX]
Reports for Purchase
Showing records 1 - 20 ( 34 total )
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Update Reinforces DNK-01 Potential in 2L MSS CRC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DKN-01 Clinical Programs on Track; New PT $5.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eyes on DisTinGuish Update in Mid-2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Promising Efficacy Reported Across 2L MSS CRC Subgroups from DeFiance Part A
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Clinical Data Updates Expected in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DKN-01 Clinical Programs Advance; Adjust PT to $7; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Data Updates From DisTinGuish and DeFianCe Studies Expected in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BeiGene?s Walkaway - a Non-Event; Multiple Catalysts in 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Merger With Flame Bioscience in All-Stock Deal; Lower PT to $2.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive DisTinGuish Updates at SITC and ESMO; Part C Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Outlined DKN-01 Development Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DisTinGuish Fully Enrolled; DKN-01 ASCO Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DisTinGuish Achieved Critical Clinical Milestone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DisTinGuish Scores its First Goal; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DisTinGuish Study Data to be Presented at ESMO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Nearing an Inflection Point in BeiGene Collaboration; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Data Readouts Expected in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DKN-01 for Endometrial Cancer Underappreciated; BeiGene Study Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Leap Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BeiGene Study to Initiate Imminently; Lower $4 PT on Dilution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S